Evolutionary Genomics Company Executives
| FNAM Stock | USD 0.0002 0.00 0.00% |
Evolutionary Genomics employs about 2 people. The company is managed by 2 executives with a total tenure of roughly 5 years, averaging almost 2.0 years of service per executive, having 1.0 employees per reported executive. Analysis of Evolutionary Genomics' management performance can provide insight into the firm performance.
| Steve Warnecke Insider CEO, Chairman |
| Walter Messier Insider CTO, Founder |
Evolutionary |
Evolutionary Genomics Management Team Effectiveness
The company has return on total asset (ROA) of (0.4538) % which means that it has lost $0.4538 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (145.2667) %, meaning that it created substantial loss on money invested by shareholders. Evolutionary Genomics' management efficiency ratios could be used to measure how well Evolutionary Genomics manages its routine affairs as well as how well it operates its assets and liabilities.Evolutionary Genomics Workforce Comparison
Evolutionary Genomics is one of the top stocks in number of employees category among its peers. The total workforce of Biotechnology industry is currently estimated at about 103,016. Evolutionary Genomics adds roughly 2.0 in number of employees claiming only tiny portion of stocks in Biotechnology industry.
Evolutionary Genomics Benchmark Summation
Operator |
The output start index for this execution was zero with a total number of output elements of sixty-one. Evolutionary Genomics Price Series Summation is a cross summation of Evolutionary Genomics price series and its benchmark/peer.
Evolutionary Genomics Notable Stakeholders
An Evolutionary Genomics stakeholder refers to an individual interested in an outcome of the business. Different stakeholders have different interests, and companies such as Evolutionary Genomics often face trade-offs trying to please all of them. Evolutionary Genomics' stakeholders can have a positive or negative influence on the entity's direction, and there are a lot of executives involved in getting Evolutionary Genomics' stock to the level that pleases all shareholders. Keeping track of the stakeholders is a great way to stay on top of things affecting its ongoing price.
| Steve Warnecke | CEO, Chairman | Profile | |
| Walter Messier | CTO, Founder | Profile |
About Evolutionary Genomics Management Performance
The success or failure of an entity such as Evolutionary Genomics often depends on how effective the management is. Evolutionary Genomics management team is responsible for propelling the future growth in the right direction and administering and controlling the business activities and accounting for the results. Ineffective management usually contributes to failure in the company's future performance for all stakeholders equally, but most importantly, for investors. So it is important to measure the effectiveness of Evolutionary management before purchasing its stock. In many ways, it's all about finding the answer to one important question - Are they doing the right thing right now? How would we assess whether the Evolutionary management is utilizing all available resources in the best possible way? Also, how well is the company doing relative to others in its sector and the market as a whole? The answer can be found by analyzing a few important fundamental indicators such as return on assets and return on equity.
Evolutionary Genomics, Inc., together with its subsidiaries, engages in the research and identification of positively selected genes in humans, animals, and commercial crops. Evolutionary Genomics, Inc. was incorporated in 1990 and is based in Castle Rock, Colorado. Evolutionary Genomics operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 2 people.
Evolutionary Genomics Workforce Analysis
Traditionally, organizations such as Evolutionary Genomics use manpower efficiency calculations for various incentive schemes, employee appraisal, or as an initiative to improve the processes. However, it can also be used by investors to make long-term investment decisions. The trends in the profit per employee or revenue per employee are measured by net income or revenue divided by the current number of full-time employees over a given time interval. Because workforce needs differ across sectors, these ratios could be used to compare Evolutionary Genomics within its industry.Evolutionary Genomics Manpower Efficiency
Return on Evolutionary Genomics Manpower
| Revenue Per Employee | 0.0 | |
| Revenue Per Executive | 0.0 | |
| Net Loss Per Employee | 1.4M | |
| Net Loss Per Executive | 1.4M |
Other Information on Investing in Evolutionary Pink Sheet
Evolutionary Genomics financial ratios help investors to determine whether Evolutionary Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Evolutionary with respect to the benefits of owning Evolutionary Genomics security.